Brooks Laboratories Ltd

Stage 1 · Basing · week 3

As of 20 Nov 2026, Brooks Laboratories is in Stage 1, the basing phase, now in week 3 (since 2 Nov 2026). It closed at ₹67.20, 37.2% below its 52-week high and above its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. More about the company

₹67.2
Close, 20 Nov 2026
-0.15% on the day
₹198 Cr · Micro cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dLabs & Life Sciences Services 33.3%0.0 pts

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

RS rank

Edge

—

BROOKS is basing for 3 weeks, above its 50-day average; it has not started an uptrend yet.

Its relative strength is 16 of 99, below the middle among NSE stocks over the past year. Labs & Life Sciences Services ranks 70 of 106 industries by the strength of its stocks.

Is BROOKS early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2023-08-24 → 2026-11-20
S2 27w
S4 16w
S4 32w
2023-08-242026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 1w → S2 27w → S3 6w → S4 16w → S1 5w → S2 11w → S3 3w → S2 9w → S3 4w → S4 7w → S1 9w → S2 10w → S3 3w → S4 32w → S1 11w → S4 9w → S1 3w current
Total tracked: 168 weeks across 17 stage runs.

BROOKS among Labs & Life Sciences Services5th of 6 by relative strength

All 6 →
Stocks in Labs & Life Sciences Services ranked by relative strength, with stage and one-month change
#StockStageRS1M
1DIVISLABStage 2 · wk 2693+21.7%
2AARTIPHARMStage 2 · wk 1384+17.5%
3VIMTALABSStage 3 · wk 530−4.3%
4SYNGENEStage 1 · wk 123+20.0%
5BROOKSStage 1 · wk 316+10.6%
6DCALStage 4 · wk 145−18.7%
vs 52W High
-37.2%
₹37.1 lo₹107 hi
37.2% below 52W high, far from high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 3
1w13w26w
Week 3, early base
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
6.3%
200 DMA: ₹63.2 · sloping down
The stock has reclaimed its 200-day average while it bases. Holding above the line is one of the things a Stage 2 advance needs.
Rel Volume
0.51x
vs 50-day avg
Volume was well below average. That is normal while a stock bases. A surge on an upside breakout is the signal to watch.
Trend Health
→
Short-term trend flat
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+10.6%
3M
+13.7%
6M
+35.7%
YTD
-16.1%
1Y
-38.8%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
Sector has 58 Stage 2 leaders. See Health Care Stage 2 →
Industry
Labs & Life Sciences Services
→ Flat
Stage 2%
33.3%
20d Δ
+0.0pp
1M return
+20.9%
3M return
+27.9%
Industry Stage-2 % · last 20 days
Industry has 2 Stage 2 leaders. See Labs & Life Sciences Services Stage 2 →

Mutual fund holdings

Held by 1 mutual funds in portfolios to October 2026: 1 active funds and 0 index funds and ETFs.

In October, no active fund changed its holding.

Largest active holders, by weight in the fund
All 1 funds and what each did in October

Mutual funds holding BROOKS: the ten largest and the month’s moves →

Fund details on DiscoverMF

Scan Membership
Not in any scan now.
Last appeared 23 Jul 2025
Recent Stage Timeline
2026-11-20S1
Wk 3 · Vol 0.51x
2026-11-19S1
Wk 3 · Vol 0.77x
2026-11-18S1
Wk 3 · Vol 0.41x
2026-11-17S1
Wk 3 · Vol 0.70x
2026-11-16S1
Wk 2 · Vol 2.74x
2026-11-13S1
Wk 2 · Vol 0.33x
2026-11-12S1
Wk 2 · Vol 0.32x
2026-11-11S1
Wk 2 · Vol 0.47x
2026-11-09S1
Wk 2 · Vol 0.22x
2026-11-06S1
Wk 1 · Vol 1.46x
2026-11-05S1
Wk 1 · Vol 0.38x
2026-11-04S1
Wk 1 · Vol 1.02x
Moving averages & range
50 DMA
₹62.9
200 DMA
₹63.2
52W High
₹107
52W Low
₹37.1
5D Low
₹67
Resistance levels (recent highs)
20d High
₹69.9
60d High
₹70.4
120d High
₹77.2
250d High
₹105.2
Next resistance
+4.0%
to 20d High
P/E (TTM)
14.3
Forward 11.0
Dividend Yield
0.00%
P/B 1.5

Brooks Laboratories: quick answers

What stage is Brooks Laboratories in?

As of 20 Nov 2026, Brooks Laboratories (BROOKS) is in Stage 1, the basing phase. It entered Stage 1 on 2 Nov 2026 and is in week 3. What the four stages mean

Is Brooks Laboratories in an uptrend?

Not yet. Brooks Laboratories is in Stage 1, a base that can come before an uptrend. It trades 6.3% above its 200-day average, which is falling.

How far is Brooks Laboratories from its 52-week high?

Brooks Laboratories closed at ₹67.20 on 20 Nov 2026, 37.2% below its 52-week high of ₹107. Its 52-week low is ₹37.11.

How has Brooks Laboratories performed over the past year?

As of 20 Nov 2026, Brooks Laboratories is down 38.8% over the past year and down 16.1% so far in 2026.

Which sector and industry is Brooks Laboratories in?

Brooks Laboratories is in the Labs & Life Sciences Services industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Health Care

About this companyHealth Care· Labs & Life Sciences Services

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company's product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also provides regulatory compliance, custom branding and packaging, scalable production, and end-to-end support services. The company serves government health programs and public sector institutions, hospitals and medical colleges, defense and railways, corporate healthcare, and NGOs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan Nigeria, Lebanon, Mauritius, Sudan, Madagascar, DR Congo, Mozambique, LATAM, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.